seralutinib

Seralutinib is an inhaled, small-molecule tyrosine kinase inhibitor developed for the treatment of pulmonary arterial hypertension (PAH). It specifically targets and inhibits platelet-derived growth factor receptor alpha (PDGFRα), platelet-derived growth factor receptor beta (PDGFRβ), colony-stimulating factor 1 receptor (CSF1R), and c-KIT proto-oncogene receptor tyrosine kinase (c-KIT) kinases, which are key drivers of pathological vascular remodeling in PAH. Seralutinib is formulated for deep lung delivery via a dry powder inhaler to maximize local efficacy while minimizing systemic exposure. Preclinical studies have shown that seralutinib can prevent progression and even reverse established PAH in animal models by reducing vascular resistance, right ventricular hypertrophy, and pulmonary arteriolar remodeling. Clinical trials have demonstrated significant reductions in pulmonary vascular resistance with good tolerability; the most common side effect is cough. The drug is currently being evaluated in Phase III clinical trials for PAH[1][3][4][5][6][7][8].

Other names

seralutinibGB002GB-002GB 002